Bayer has agreed to a $7.25 billion class action settlement to resolve claims from people who developed Non-Hodgkin Lymphoma (NHL) after exposure to Roundup and other glyphosate-based herbicides. The settlement received preliminary approval on March 4, 2026, from a Missouri circuit court judge and represents one of the largest toxic tort settlements in U.S. history.
Rather than a single upfront payment, Bayer will fund the settlement through annual payments over 17 to 21 years, allowing the company to spread the financial impact while claimants receive compensation over an extended period. The settlement is significant because it covers both people already diagnosed with NHL from past Roundup exposure and individuals who will be diagnosed in the future—up to 16 years from the settlement date. With approximately 40,000 expected claimants and roughly 65,000 Roundup-related claims still pending as of March 2026, this settlement resolves a substantial portion of the litigation that has dogged Bayer since its acquisition of Monsanto in 2018.
Table of Contents
- Who Qualifies for the Roundup Non-Hodgkin Lymphoma Settlement?
- How Much Money Can You Expect to Receive?
- What Is the Timeline and What Are the Critical Deadlines?
- How Will Payments Be Structured?
- What Should You Do Now If You Have a Roundup-Related NHL Claim?
- Why Did Bayer Agree to This Large Settlement?
- Understanding the 16-Year Future Claimants Window
Who Qualifies for the Roundup Non-Hodgkin Lymphoma Settlement?
To qualify for this settlement, you must have been exposed to Roundup (or other glyphosate-based herbicides) before February 17, 2026, and you must have been diagnosed with Non-Hodgkin Lymphoma. The settlement covers occupational exposures—agricultural workers, landscapers, turf managers, and other professionals who used Roundup regularly—as well as residential exposures for homeowners and gardeners. The key difference is that occupational exposures typically result in higher settlement amounts because they reflect more intensive and prolonged contact with the product. The settlement also covers “future claimants,” a crucial provision for people who have not yet been diagnosed. If you were exposed to Roundup but have not yet developed NHL, you have up to 6 years from the date you receive an NHL diagnosis to file a claim under this settlement.
This 16-year window (from March 2026 forward) means that people exposed years ago but not yet diagnosed are protected. However, the deadline for the exposure itself was February 17, 2026—any exposure after that date falls outside the settlement’s scope. A practical example: a former golf course superintendent who regularly applied Roundup from 2010 to 2015 and was diagnosed with NHL in 2023 clearly qualifies. So does a homeowner who used Roundup on her lawn for 20 years and was just diagnosed in 2026. However, someone exposed to glyphosate for the first time in March 2026 would not qualify, even if they later develop NHL, because their exposure occurred after the cutoff date.
How Much Money Can You Expect to Receive?
Payout amounts range from $6,000 to $165,000, with the specific award depending on your occupation, duration of exposure, age at diagnosis, and the aggressiveness of your NHL diagnosis. The settlement includes a structured grid that ties compensation to these factors. Agricultural, industrial, and turf workers with documented long-term exposure to Roundup who developed aggressive NHL before age 60 can expect awards averaging around $165,000. This reflects both the intensity of their exposure and the severity of their diagnosis. Residential users fall into lower payout categories.
Someone who used Roundup occasionally on their residential property and was diagnosed with NHL between ages 60 and 77 might receive an average of $20,000. For claimants diagnosed at age 78 or older, the average award is $10,000, with a quick-pay option available for $6,000 if you want faster processing without a lengthy claims review. These lower amounts do not necessarily mean the claim is less valid; rather, they reflect the settlement’s assessment of exposure intensity and diagnosis characteristics. The settlement includes a provision for differential damages based on NHL subtype and stage at diagnosis. More aggressive forms of NHL diagnosed at earlier stages typically receive higher compensation than less aggressive diagnoses or those identified at later stages. However, if you worked with Roundup for many years but are only now being diagnosed, your occupational history is what matters most—the settlement recognizes that occupational exposure carries different weight than casual residential use.
What Is the Timeline and What Are the Critical Deadlines?
The settlement is not yet final. Key dates you must know: the opt-out deadline is June 4, 2026, and the final approval hearing is scheduled for July 9, 2026. If you want to remain part of the settlement and be eligible for compensation, you must not opt out by June 4. The final approval hearing will give the court an opportunity to review any objections and formally approve or modify the settlement terms. Once final approval is granted, claims administration will begin. The opt-out deadline is critical.
If you opt out of the settlement, you preserve your right to sue Bayer independently but you give up the potential compensation available through the settlement. This is a significant tradeoff: the settlement offers a certain payout amount with a defined process, while opting out means you must pursue individual litigation with uncertain outcomes and potentially much longer delays. Only opt out if you believe your individual claim is worth substantially more than what the settlement grid offers, which is rarely the case given litigation costs and uncertainty. For future claimants—people not yet diagnosed—you have 6 years from your NHL diagnosis date to file a claim. This is a generous window and means you should not rush if you are still in diagnosis or treatment. However, do not delay indefinitely; once that 6-year window closes, you lose the right to claim under this settlement.
How Will Payments Be Structured?
Rather than paying the full $7.25 billion immediately, Bayer will fund the settlement through annual installment payments over 17 to 21 years. This structure means you will not receive your full award in a single check; instead, you will receive periodic payments over many years. The advantage to Bayer is cash flow management; the advantage to claimants is that the settlement actually comes through without depleting the company’s resources and triggering potential insolvency, which would leave claims unpaid. For claimants, the key question is whether they will live long enough to receive their full awards.
Someone diagnosed with NHL at age 55 might expect to receive their full settlement amount over time, but someone diagnosed at age 80 should understand that they may not receive the entire award if payments extend over 17+ years. The settlement likely includes provisions for deceased claimants’ estates to receive remaining payments, but you should confirm this during the claims process. This is a significant limitation of structured settlements: the longer the funding period, the greater the risk that individual claimants will not see the full amount. The settlement administrator will manage payment logistics, so you will not deal with Bayer directly once your claim is approved. You will receive clear instructions on payment frequency and method when your claim is processed.
What Should You Do Now If You Have a Roundup-Related NHL Claim?
Your first step is to document your Roundup exposure history. Gather any records showing when and how you used Roundup—employment records, receipts, photographs, or contemporaneous notes. If you worked in agriculture, landscaping, or turf management, your employer’s records or safety data sheets (SDS) may be available. If you used Roundup residentially, any purchase records from retailers help establish your use pattern. The more documentation you can provide, the smoother your claims process will be. Next, obtain a copy of your NHL diagnosis and medical records. The claims administrator will need official documentation of your diagnosis, including the specific NHL subtype and stage if available.
Contact your oncologist’s office to request these records now; medical offices can be slow, so starting this process early ensures you have everything ready before the claims window closes. Finally, do not wait until the last moment to file. Once the settlement is finally approved (expected in July 2026), the claims process will begin. While future claimants have 6 years from diagnosis, it is much easier to file while you remember your exposure history and while documents are more accessible. If you were exposed occupationally, reach out to former colleagues or supervisors who might corroborate your exposure claims. A key warning: be cautious of third-party claims advisors or law firms that charge large contingency fees. The settlement includes attorneys’ fees provisions, and you have the right to seek legal representation at no upfront cost if attorneys are willing to work on contingency under the settlement’s fee structure. If someone approaches you offering to help with your claim, understand their fee structure before signing anything.
Why Did Bayer Agree to This Large Settlement?
Bayer has faced mounting legal losses in Roundup litigation since acquiring Monsanto in 2018. In May 2025, a Missouri appellate court affirmed a $611 million verdict against Monsanto in a single case, validating the scientific evidence linking glyphosate exposure to NHL and signaling that juries were prepared to award substantial damages. Bayer has already spent more than $10 billion resolving Roundup cases over the past several years, with no end to litigation in sight.
The $7.25 billion settlement allows Bayer to resolve the vast majority of pending claims with a defined, capped liability. From the company’s perspective, this is preferable to continuing to face individual jury trials, where unpredictable verdicts could result in even larger total payouts. The settlement provides certainty and closure—or at least closure on this batch of claims—allowing the company to move forward without the ongoing uncertainty of thousands of pending lawsuits.
Understanding the 16-Year Future Claimants Window
One of the settlement’s most unusual features is its coverage of future claimants—people who will be diagnosed with NHL sometime in the next 16 years (through March 2042) but were exposed to Roundup before February 17, 2026. This is not common in mass tort settlements and reflects a recognition that NHL can have a latency period; people exposed years ago may not develop symptoms for a long time. The settlement accounts for this biological reality.
The benefit of this provision is clear for anyone who was heavily exposed to Roundup years ago but has not yet developed NHL. You are protected by this settlement even if your diagnosis comes a decade from now. However, the tradeoff is that settlements covering future claimants typically assume higher claim administration costs and uncertainty around the final number of claimants, which influences individual payout amounts.